Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.

Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW.

Cell Metab. 2016 Nov 8;24(5):728-739. doi: 10.1016/j.cmet.2016.09.005.

PMID:
27746051
2.

Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.

Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF, Romero IL.

PLoS One. 2016 Jan 20;11(1):e0147145. doi: 10.1371/journal.pone.0147145.

3.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

4.

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.

Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL.

Oncotarget. 2015 Sep 15;6(27):23548-60.

5.

Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.

Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E.

Clin Cancer Res. 2015 Feb 15;21(4):680-6. doi: 10.1158/1078-0432.CCR-14-2198. Review.

6.

Old drug, new trick: repurposing metformin for gynecologic cancers?

Febbraro T, Lengyel E, Romero IL.

Gynecol Oncol. 2014 Dec;135(3):614-21. doi: 10.1016/j.ygyno.2014.10.011. Review.

7.

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL.

Am J Obstet Gynecol. 2015 Apr;212(4):479.e1-479.e10. doi: 10.1016/j.ajog.2014.10.026.

8.

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E.

J Clin Invest. 2014 Oct;124(10):4614-28. doi: 10.1172/JCI74778.

9.

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.

Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL.

PLoS One. 2014 Aug 13;9(8):e104521. doi: 10.1371/journal.pone.0104521.

10.

Adipose tissue and adipocytes support tumorigenesis and metastasis.

Nieman KM, Romero IL, Van Houten B, Lengyel E.

Biochim Biophys Acta. 2013 Oct;1831(10):1533-41. doi: 10.1016/j.bbalip.2013.02.010. Review.

11.

Evaluation of silicon oil on bacterial growth.

Adams F, Romero IL, Silva CB, Manzano RP.

Arq Bras Oftalmol. 2012 Mar-Apr;75(2):89-91.

12.

The use of 1% toluidine blue eye drops in the diagnosis of ocular surface squamous neoplasia.

Romero IL, Barros Jde N, Martins MC, Ballalai PL.

Cornea. 2013 Jan;32(1):36-9. doi: 10.1097/ICO.0b013e318243f61f.

PMID:
22525782
13.

Direct fluorescent antibody assay and polymerase chain reaction for the detection of Chlamydia trachomatis in patients with vernal keratoconjunctivitis.

Nishiwaki-Dantas MC, de Abreu MT, de Melo CM, Romero IL, Neto RB, Dantas PE.

Clinics (Sao Paulo). 2011;66(12):2013-8.

14.

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E.

Obstet Gynecol. 2012 Jan;119(1):61-7. doi: 10.1097/AOG.0b013e3182393ab3.

15.

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E.

Nat Med. 2011 Oct 30;17(11):1498-503. doi: 10.1038/nm.2492.

16.

The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.

Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E.

Gynecol Oncol. 2012 Jan;124(1):134-41. doi: 10.1016/j.ygyno.2011.08.026.

17.

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E.

Clin Cancer Res. 2011 Jun 15;17(12):4042-51. doi: 10.1158/1078-0432.CCR-10-3387.

18.

CD95 promotes tumour growth.

Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME.

Nature. 2010 May 27;465(7297):492-6. doi: 10.1038/nature09075. Erratum in: Nature. 2011 Jul 14;475(7355):254. Nature. 2011 Mar 10;471(7337):254. Nature. 2012 Nov 29;491(7426):784.

19.

[Epstein-Barr virus bilateral dacryoadenitis: case report].

Moscovici BK, Romero IL, Vital Filho J, Bison SH.

Arq Bras Oftalmol. 2009 Nov-Dec;72(6):826-8. Portuguese.

20.

Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.

Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E.

Cancer Prev Res (Phila). 2009 Sep;2(9):792-9. doi: 10.1158/1940-6207.CAPR-08-0236.

Items per page

Supplemental Content

Loading ...
Support Center